Search

Your search keyword '"Córdoba, Raúl"' showing total 59 results

Search Constraints

Start Over You searched for: Author "Córdoba, Raúl" Remove constraint Author: "Córdoba, Raúl" Journal blood Remove constraint Journal: blood
59 results on '"Córdoba, Raúl"'

Search Results

1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

2. Real-World Evidence of Collecting Quality of Life (QoL) and Symptoms Perception Using the HM-PRO© Tool As a Patient-Reported Outcome Measure (PROM) in Patients with Lymphoma While Receiving Intravenous Chemotherapy

3. Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

4. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

5. Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

6. Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

7. Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

9. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

11. Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

12. A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

14. Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

16. Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

17. Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

19. Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

20. Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

21. Decoding the Historical TALE: COVID-19 Impact on Hematological Malignancy Patients - Insights from 2020 to 2022

22. Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

23. Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

24. Worldwide Examination of Patients with CLL Hospitalized for COVID-19

26. Feasibility of Electronic Patient-Reported Outcome (ePRO) Measurement Using PRO-CTCAE® Questionnaire to Improve Quality of Life Assessment and Healthcare Resources Management in Patients with Lymphoma Receiving Intravenous Chemotherapy

27. Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

30. A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

31. Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

32. Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

33. Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

35. Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

38. Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population

39. Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project

40. Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy

41. Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

42. Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era

45. High Correlation Clinical Responses to 1st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

46. Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

47. CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma

48. Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study

49. CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

50. Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity

Catalog

Books, media, physical & digital resources